Scheiflinger F, Dorner F, Falkner F G
Immuno AG, Orth/Donau, Austria.
Arch Virol. 1998;143(3):467-74. doi: 10.1007/s007050050303.
Recombinant vaccinia viruses based on the highly attenuated Modified Vaccinia Ankara (MVA) strain expressing HIV-1 antigen genes were constructed by a novel procedure involving the transient use of two marker genes. The selectable markers used, the Escherichia coli guanine phosphoribosyltransferase (gpt) and the beta-galactosidase (lacZ) genes, are not retained within the final recombinant virus. The transient marker stabilisation (TMS) procedure allows the generation of marker-free recombinant viruses in a series of simple plaque purification steps. HIV-1 gag pol genes were inserted into two loci of vaccinia MVA demonstrating the efficiency of the procedure.
基于表达HIV-1抗原基因的高度减毒的安卡拉痘苗病毒(MVA)株构建重组痘苗病毒,这是通过一种涉及短暂使用两个标记基因的新方法实现的。所使用的选择标记,即大肠杆菌鸟嘌呤磷酸核糖转移酶(gpt)基因和β-半乳糖苷酶(lacZ)基因,不会保留在最终的重组病毒中。短暂标记稳定化(TMS)方法允许在一系列简单的噬斑纯化步骤中产生无标记的重组病毒。将HIV-1 gag pol基因插入痘苗病毒MVA的两个位点,证明了该方法的有效性。